Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma

ABSTRACT: Patients with multiple myeloma refractory to standard treatments have short survival. High PDIA1 expression confers resistance to proteasome inhibitors and other stressors due to the gain in ER-function, while maintaining or increasing vulnerability to PDIA1 inhibition. In this study we report the identification and characterization of an orally bioavailable novel PDIA1 inhibitor CCF642-34 that is effective against multiple myeloma in pre-clinical models.

ORGANISM(S): Homo sapiens

PROVIDER: GSE167097 | GEO | 2021/02/20

REPOSITORIES: GEO